Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s share price dropped 5.4% on Wednesday . The company traded as low as $8.72 and last traded at $8.70. Approximately 408,065 shares were traded during trading, a decline of 72% from the average daily volume of 1,443,480 shares. The stock had previously closed at $9.19.
Ginkgo Bioworks Price Performance
The company has a market capitalization of $561.42 million, a P/E ratio of -1.05 and a beta of 1.25. The stock's fifty day simple moving average is $7.86 and its 200-day simple moving average is $9.03.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The business had revenue of $48.32 million for the quarter, compared to analyst estimates of $38.70 million. Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. On average, research analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.
Institutional Investors Weigh In On Ginkgo Bioworks
Several hedge funds and other institutional investors have recently modified their holdings of DNA. SBI Securities Co. Ltd. bought a new stake in Ginkgo Bioworks in the 4th quarter valued at $29,000. US Bancorp DE increased its holdings in shares of Ginkgo Bioworks by 43.5% during the 1st quarter. US Bancorp DE now owns 6,302 shares of the company's stock worth $36,000 after purchasing an additional 1,911 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Ginkgo Bioworks during the fourth quarter valued at about $46,000. CWM LLC lifted its stake in shares of Ginkgo Bioworks by 667.6% in the first quarter. CWM LLC now owns 12,274 shares of the company's stock valued at $70,000 after buying an additional 10,675 shares during the period. Finally, Fox Run Management L.L.C. bought a new stake in shares of Ginkgo Bioworks in the first quarter valued at about $76,000. Institutional investors and hedge funds own 78.63% of the company's stock.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Recommended Stories
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
